Trial Profile
A Phase II Study of Neoadjuvant Chemotherapy With Docetaxel, Capecitabine, Cisplatin, and Bevacizumab in Patients With Unresectable Advanced Gastric Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine; Cisplatin; Docetaxel
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 08 May 2019 Status changed from active, no longer recruiting to completed.
- 13 Jul 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
- 13 Jul 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2019.